Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDP58 plus mesalazine versus high-dose mesalazine in moderately active ulcerative colitis
2004-004077-29Phase 2Completed
- Sponsor
- Procter & Gamble
- Start
- Dec 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RDP58 in autoimmune colitis (3 arms), sponsored by Procter & Gamble. Primary endpoint: Complete remission at Day 56. Started Dec 2004; status: completed.
02
Drugs
RDP58
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-004077-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004077-29.